PUMA BIOTECHNOLOGY, INC. (PBYI) Free cash flow 2016–2025
PUMA BIOTECHNOLOGY, INC. (PBYI) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$41.7MFY2025 · since FY2016: -$146.0M → $41.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $41.7M | +7.4% |
| FY2024 | $38.9M | +44.6% |
| FY2023 | $26.9M | +269.8% |
| FY2022 | -$15.8M | -176.6% |
| FY2021 | $20.6M | +2740.4% |
| FY2020 | $727,000 | -96.7% |
| FY2019 | $22.1M | +189.9% |
| FY2018 | -$24.5M | +85.8% |
| FY2017 | -$172.9M | -18.4% |
| FY2016 | -$146.0M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More PBYI financial trends
PBYI RevenuePBYI Net incomePBYI Net marginPBYI Gross profitPBYI Gross marginPBYI Operating incomePBYI Operating marginPBYI Operating cash flowPBYI Capital expendituresPBYI Return on equityPBYI Stock buybacksPBYI Dividends paidPBYI Total assetsPBYI Total liabilitiesPBYI Shareholders’ equityPBYI overview →